Skip to main content
ADVANCED SEARCH
Log in
Top
Diabetes Therapy
Published in:

Open Access 21-01-2023 | Insulins | Review

Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review

Authors: Ana Rita Soares, Marisa Coelho, Marsha Tracey, Davide Carvalho, José Silva-Nunes

Published in: Diabetes Therapy | Issue 2/2023

Login to get access

Abstract

Introduction

The aim of this review was to identify and review studies reporting on the epidemiological, social and economic impact associated with severe hypoglycaemia (SH) in people with diabetes mellitus (DM) in Portugal.

Methods

A structured literature search was carried out in PubMed and Embase using a predefined selection criterion. Studies published in either Portuguese or English, between January 2010 and February 2021 were deemed eligible for inclusion.

Results

Twelve studies including adults (aged ≥ 18 years) with type 1 and/or type 2 diabetes mellitus (T1DM/T2DM) were eligible for inclusion. Epidemiological estimates varied according to the setting and type of data source used. The proportion of patients who experienced ≥ 1 SH episode (SHE) in the previous 6–12 months varied from 3.1% in adults with T2DM to 36.8% in adults with T1DM. In adults with T2DM the prevalence in a community-based study was highest in the insulin and secretagogue combination treated group (9.1%), while in an emergency department setting prevalence was highest in the insulin-based therapy group and the oral hypoglycaemic agent without secretagogues group (32.0% and 20.0%, respectively). The prevalence of SH in other studies in patients with DM ranged from 0.1% (emergency department) to 18.1% (hospital ward). Patients treated with secretagogues had the highest rates of hospitalisations. In patients with T1DM, the annual rate of SHE was higher in those with impaired hypoglycaemia awareness than in those with intact awareness. Mean total cost (direct and indirect) per SHE ranged from €1493.00 in patients with T2DM treated in an emergency setting to €2608.51 in patients with T1DM who were hospitalised.

Conclusion

Hypoglycaemic events, especially SHE, have a significant effect on the life of persons living with DM and their caregivers. Studies show that the prevalence of this acute complication of diabetes is not negligible. In addition to the negative impact on the quality of life, the burden of SHE in Portugal translates into a significant impact on the global health expenditure.
Appendix
Available only for authorised users
Literature
1.
2.
Nathan DM, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.PubMedCrossRef
3.
Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89.PubMedCrossRef
4.
Association AD. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2021. Diabetes Care. 2021;44(1):111–1124.CrossRef
5.
Raposo JF. Diabetes: factos e Números 2016, 2017 e 2018. Revista Portuguesa de Diabetes. 2020;15(1):19–27.
6.
IDF. <IDF_Atlas_10th_Edition_2021.pdf>. 2021.
7.
Risso T, Furtado C. Rational use of blood glucose test strips for self-monitoring in patients with diabetes mellitus: economic impact in the Portuguese healthcare system. Diabetes Res Clin Pract. 2017;134:161–7.PubMedCrossRef
8.
Tavares AI, Marques I. Multi-layer health insurance coverage, medical services use and health in a Universal National Health System, the case of Portugal. Eur J Health Econ. 2021;22(1):141–53.PubMedCrossRef
9.
Williams R, et al. Global and regional estimates and projections of diabetes-related health expenditure: results from the international diabetes federation diabetes atlas. Diabetes Res Clin Pract. 2020;162:108072.PubMedCrossRef
10.
11.
Alao S, et al. Hypoglycemic episodes in hospitalized people with diabetes in Portugal: the HIPOS-WARD study. Clin Diabet Endocrinol. 2021;7(1):2.CrossRef
12.
American Diabetes Association Professional Practice. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S83–96.CrossRef
13.
Towler DA, et al. Mechanism of awareness of hypoglycemia. Perception of neurogenic (predominantly cholinergic) rather than neuroglycopenic symptoms. Diabetes. 1993;42(12):1791–8.PubMedCrossRef
14.
Silbert R, et al. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep. 2018;18(8):53.PubMedPubMedCentralCrossRef
15.
American Diabetes Association (ADA). 4. Comprehensive medical evaluation and assessment of comorbidities: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S40-s52.CrossRef
16.
Dømgaard M, et al. Individual and societal consequences of hypoglycemia: a cross-sectional survey. Postgrad Med. 2015;127(5):438–45.PubMedCrossRef
17.
Rossi MC, et al. Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study. Nutr Metab Cardiovasc Dis. 2019;29(7):736–43.PubMedCrossRef
18.
Ampudia-Blasco FJ, et al. Conversations and reactions around severe hypoglycaemia (CRASH): Spanish results of a global survey of people with type 1 diabetes or insulin-treated type 2 diabetes and caregivers. Endocrinol Diabetes Nutr. 2021;2:2.
19.
Hoskins N, Tikkanen CK, Pedersen-Bjergaard U. The economic impact of insulin-related hypoglycemia in Denmark: an analysis using the local impact of hypoglycemia tool. J Med Econ. 2017;20(4):363–70.PubMedCrossRef
20.
Parekh W, et al. The economic burden of insulin-related hypoglycemia in adults with diabetes: an analysis from the perspective of the Italian healthcare system. Diabetes Ther. 2018;9(3):1037–47.PubMedPubMedCentralCrossRef
21.
International Diabetes Federation (IDF). IDF Diabetes Atlas 2019, 9th edition. 2019.
22.
Conceicao J, et al. Severe hypoglycaemia among patients with type 2 diabetes requiring emergency hospital admission: the hypoglycaemia in Portugal observational study-emergency room (HIPOS-ER). Diabetes Obes Metab. 2018;20(1):50–9.PubMedCrossRef
23.
Ferreira JP, et al. Hospitalization costs due to hypoglycemia in patients with diabetes: a microcosting approach. Diabetes Therapy. 2020;11(10):2237–55.PubMedPubMedCentralCrossRef
24.
Laires PA, et al. The cost of managing severe hypoglycemic episodes in type 2 diabetic patients. Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):315–25.PubMedCrossRef
25.
Torre C, et al. Real-world prevalence of mild to moderate hypoglycemic episodes in type 2 diabetes in Portugal: results from the HIPOS-PHARMA study. Prim Care Diabetes. 2018;12(6):537–46.PubMedCrossRef
26.
Sepulveda E, et al. Differentiating hypoglycemia awareness status from hypoglycemia experience in tools for measuring impaired awareness of hypoglycemia. Diabetes Technol Ther. 2020;22(7):541–5.PubMedPubMedCentralCrossRef
27.
Azevedo S, et al. The impact of prolonged use of continuous subcutaneous insulin infusion in the control of type-1 diabetes. Acta Med Port. 2022;32(1):17–24.CrossRef
28.
Pereira CA, Almeida R, Dores J. Characteristics of hypoglycaemic episodes in diabetic patients treated at the emergency room of a Portuguese tertiary centre, 2012–2016. Endocrinol Diabet Metab. 2020;3(3):e00150.CrossRef
29.
Pereira M, Tavares H, Carvalho AJ. O Impacto da Hipoglicemia no Resul-tado Clínico de Doentes Diabéticos Não-críticos Internados em Serviços Médicos: Um Estudo de Caso-controlo. Revista Portuguesa de Diabetes. 2016;11(1):3–9.
30.
Esteves C, et al. Severe hypoglycaemia in diabetic patients in pre-hospital and emergency department care: a cross-sectional survey. BMC Res Notes. 2018;11(1):249.PubMedPubMedCentralCrossRef
31.
Marques A, et al. Estudo HiposRainha–Hipoglicémias Severas Numa Viatura Médica de Emergência e Reanimação. Revista Portuguesa de Diabetes. 2019;14(1):3–10.
32.
Coelho JF, et al. Caracterização das hipoglicémias severas em doentes diabéticos assistidos por uma viatura médica de emergência e reanimação. Revista Portuguesa de Diabetes. 2010;5(3):100–5.
33.
Pereira M, et al. Trends in prevalence of diabetes mellitus and mean fasting glucose in Portugal (1987–2009): a systematic review. Public Health. 2014;128(3):214–21.PubMedCrossRef
34.
Little S, et al. Comparison of optimised MDI versus pumps with or without sensors in severe hypoglycaemia (the hypo COMPaSS trial). BMC Endocr Disord. 2012;12(1):33.PubMedPubMedCentralCrossRef
35.
Gold AE, Macleod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care. 1994;17(7):697–703.PubMedCrossRef
36.
Núñez M, et al. Epidemiology, quality of life, and costs associated with hypoglycemia in patients with diabetes in spain: a systematic literature review. Diabetes Therapy. 2019;10(2):375–92.PubMedPubMedCentralCrossRef
37.
Donnelly LA, et al. Frequency and predictors of hypoglycaemia in type 1 and insulin-treated type 2 diabetes: a population-based study. Diabet Med. 2005;22(6):749–55.PubMedCrossRef
38.
Elliott L, et al. Hypoglycemia event rates: a comparison between real-world data and randomized controlled trial populations in insulin-treated diabetes. Diabetes Ther. 2016;7(1):45–60.PubMedPubMedCentralCrossRef
39.
Khunti K, et al. Rates and predictors of hypoglycaemia in 27 585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. Diabetes Obes Metab. 2016;18(9):907–15.PubMedPubMedCentralCrossRef
40.
41.
Kloos C, et al. Reduction of severe hypoglycaemia in people with type 2 diabetes after a structured inpatient intervention. 2019.
42.
43.
American Diabetes Association (ADA). 6. Glycemic targets: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S73-s84.CrossRef
44.
Jakubczyk M, et al. Cost of severe hypoglycaemia in nine European countries. J Med Econ. 2016;19(10):973–82.PubMedCrossRef
45.
Hammer M, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–90.PubMedCrossRef
46.
Aazza S, et al. Antioxidant, anti-inflammatory and anti-hyperglycaemic activities of essential oils from thymbra capitata, thymus albicans, thymus caespititius, thymus carnosus, thymus lotocephalus and thymus mastichina from Portugal. Nat Prod Commun. 2022;11(7):1029–38.
Metadata
Title
Epidemiological, Social and Economic Burden of Severe Hypoglycaemia in Patients with Diabetes Mellitus in Portugal: A Structured Literature Review
Authors
Ana Rita Soares
Marisa Coelho
Marsha Tracey
Davide Carvalho
José Silva-Nunes
Publication date
21-01-2023
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 2/2023
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-022-01358-1

Other articles of this Issue 2/2023

Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers

Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300): Results from the REALI Pooled Database

STYLCONNECT Study: An Assessment of Automatic Data Collection Devices by People Living with Diabetes and Using an Insulin Pen

  • Open Access
  • Insulins
  • Original Research

Practical Guidance for Healthcare Providers on Collaborating with People with Type 2 Diabetes: Advancing Treatment and Initiating Injectable Therapy

  • Open Access
  • Insulins
  • Practical Approach

Pilot Trial on the Effect of 5-Aminolevulinic Acid on Glucose Tolerance in Patients with Maternally Inherited Diabetes and Deafness

Independent and Joint Associations of Age, Pre-pregnancy BMI, and Gestational Weight Gain with Adverse Pregnancy Outcomes in Gestational Diabetes Mellitus

Keynote series | Spotlight on managing health in obesity

Obesity is a major contributor to cardiorenal metabolic disease, but its impact extends throughout the body. Understand how obesity can affect other organ systems and impact treatment, and whether weight-loss measures improve outcomes.

Prof. Eva L. Feldman
Prof. Jonette Keri
Developed by: Springer Medicine
Watch now
Video

Women’s health knowledge hub

Elevate your patient care with our comprehensive, evidence-based medical education on women's health. Designed to help you provide exceptional care for your female patients at every stage of life, we provide expert insights into topics such as reproductive health, menopause, breast cancer and sex-specific health risks and precision medicine.

Read more

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar
Image Credits